Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The Immune Response Corporation
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
HIV-1 seropositivity.
CD4 counts \>= 550 cells/ml.
NOTE:
If a patient's CD4 count is 550 to 600 cells/ml, the patient must either rescreen within 30 days for Study 806 or wait 6 months before entering the expanded access program.
Patient must have failed or been intolerant to other comparable or alternative marketed therapies or must not be a candidate for such therapies.
Patient must have laboratory tests within specified limits.
You may not be if
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
Clinically significant cardiac, hepatic, renal or gastrointestinal dysfunction.
Current participation in a Remune study.
Concurrent Medication:
Excluded:
Use of any immune-modulating drugs.
Induction therapy or initiation of new treatment regimen for an AIDS-defining condition.
Current participation in a Remune study.
Patients with any of the following prior conditions are excluded:
Previous participation in a Remune study.
Prior Medication:
Excluded:
Previous participation in a Remune study.
Excluded within 30 days of study entry:
Use of any immune-modulating drugs.
Induction therapy or initiation of new treatment regimen for an AIDS-defining condition within 30 days of Day 1 visit.
